Axon Enterprise, Inc $AXON Position Decreased by Ulland Investment Advisors LLC

Ulland Investment Advisors LLC lowered its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 27.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,791 shares of the biotechnology company’s stock after selling 4,148 shares during the period. Axon Enterprise makes up 6.8% of Ulland Investment Advisors LLC’s investment portfolio, making the stock its 2nd largest position. Ulland Investment Advisors LLC’s holdings in Axon Enterprise were worth $8,934,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. LaSalle St. Investment Advisors LLC increased its stake in Axon Enterprise by 2.1% in the 1st quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company’s stock worth $408,000 after purchasing an additional 16 shares during the period. Smartleaf Asset Management LLC grew its position in shares of Axon Enterprise by 5.0% in the 1st quarter. Smartleaf Asset Management LLC now owns 379 shares of the biotechnology company’s stock worth $203,000 after buying an additional 18 shares during the last quarter. Pinion Investment Advisors LLC increased its stake in shares of Axon Enterprise by 3.0% during the first quarter. Pinion Investment Advisors LLC now owns 649 shares of the biotechnology company’s stock valued at $341,000 after buying an additional 19 shares during the period. Kentucky Retirement Systems raised its holdings in shares of Axon Enterprise by 0.4% during the first quarter. Kentucky Retirement Systems now owns 4,953 shares of the biotechnology company’s stock valued at $2,605,000 after acquiring an additional 19 shares in the last quarter. Finally, WCM Investment Management LLC lifted its stake in Axon Enterprise by 0.8% in the first quarter. WCM Investment Management LLC now owns 2,441 shares of the biotechnology company’s stock worth $1,306,000 after acquiring an additional 19 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Raymond James Financial reaffirmed an “outperform” rating and issued a $855.00 price target (up previously from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $870.00 price target on shares of Axon Enterprise in a research note on Wednesday, September 24th. Zacks Research lowered Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 2nd. JMP Securities reaffirmed a “market outperform” rating and issued a $825.00 price target on shares of Axon Enterprise in a research note on Monday, September 29th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Axon Enterprise in a research note on Wednesday. Fourteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $841.64.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $734.04 on Friday. Axon Enterprise, Inc has a fifty-two week low of $422.38 and a fifty-two week high of $885.91. The business has a 50-day simple moving average of $756.36 and a two-hundred day simple moving average of $711.76. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The firm has a market cap of $57.63 billion, a price-to-earnings ratio of 181.24, a price-to-earnings-growth ratio of 28.25 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. During the same quarter in the previous year, the firm earned $1.20 EPS. Axon Enterprise’s revenue was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. On average, analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Brittany Bagley sold 5,000 shares of the company’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the completion of the sale, the chief financial officer owned 93,592 shares in the company, valued at approximately $66,813,456.96. This represents a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Hadi Partovi acquired 1,358 shares of Axon Enterprise stock in a transaction that occurred on Wednesday, August 13th. The shares were purchased at an average price of $740.00 per share, with a total value of $1,004,920.00. Following the transaction, the director owned 237,938 shares of the company’s stock, valued at $176,074,120. The trade was a 0.57% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 59,932 shares of company stock worth $45,115,616 in the last quarter. Insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.